Ahn J et al. Phase II study of gemcitabine and capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Proc ASCO 2005;Abstract 895.

Alba E et al; Spanish Breast Cancer Research Group. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 2004;22(13):2587-93. Abstract

Albain KS et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. Proc ASCO 2004;Abstract 510.

Andres R et al. Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer 2005;6(2):158-62. Abstract

Bajetta E et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005;23(10):2155-61. Abstract

Baweja M et al. Phase II trial of oral vinorelbine for treatment of metastatic breast cancer in women 65 years and older: N003A. Proc ASCO 2005;Abstract 740.

Bayo J et al. Docetaxel followed by capecitabine as first-line chemotherapy in metastatic breast cancer patients: Preliminary results. Proc ASCO 2005;Abstract 854.

Berruti A et al. Paclitaxel, vinorelbine and 5- fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines. Br J Cancer 2005;92(4):634-8. Abstract

Biganzoli L et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 2002;20(14):3114-21. Abstract

Blum JL et al. A Phase II trial of combination therapy with capecitabine (C) and weekly paclitaxel (P) for metastatic breast cancer (MBC): Preliminary results in taxane-naive patients. Poster presentation. San Antonio Breast Cancer Symposium 2004;Abstract 5053.

Blum JL et al. ABI-007 nanoparticle paclitaxel: Demonstration of anti-tumor activity in taxanerefractory metastatic breast cancer. Proc ASCO 2003;Abstract 64.

Bontenbal M et al. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: Results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 2005;23(28):7081-8. Abstract

Bria E et al. Impact of taxanes in association with anthracyclines in 1st line chemotherapy for metastatic breast cancer (MBC): Comprehensive review of 2805 patients in 7 phase III trials. Proc ASCO 2004;Abstract 659.

Chan S et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study. Proc ASCO 2005;Abstract 581.

Chun JH et al. Frontline docetaxel (T)/ capecitabine (X) combination therapy in patients (pts) with metastatic breast cancer (MBC): A phase II study. Proc ASCO 2004;Abstract 778.

Clemons MJ et al. Palliative chemotherapy with vinorelbine or capecitabine in women with anthracycline and taxane refractory metastatic breast cancer. Proc ASCO 2004;Abstract 773.

Estevez LG et al. Phase II study with the combination of capecitabine (C) and vinorelbine (V) in metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes. Proc ASCO 2004;Abstract 748.

Evans TR et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An angloceltic cooperative oncology group study. J Clin Oncol 2005;23(13):2988-95. Abstract

Feher O et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: A multicenter, randomized, phase III study. Ann Oncol 2005;16(6):899-908. Abstract

Ghosn M et al. Vinorelbine (N)-capecitabine (C) combination in advanced breast cancer (ABC): Long-term results of two multicentric phase II trials. Proc ASCO 2005;Abstract 673.

Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-7803. Abstract

Gradishar WJ et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: A multicenter phase II study. J Clin Oncol 2004;22(12):2321-7. Abstract

Gralow J et al. SWOG S0102: A phase II study of docetaxel (DOC) and vinorelbine (VNR) + filgrastim for HER-2 negative, stage IV breast cancer. Proc ASCO 2005;Abstract 567.

Grecea D et al. A phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Proc ASCO 2005;Abstract 736.

Ibrahim NK et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005;23(25):6019-26. Abstract

Jones SE et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005;23(24):5542-51. Abstract

Jones S et al. Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer. Breast Cancer Res Treat 2003;Abstract 10.

Katsumata N et al. Phase III trial of doxorubicin (A)/cyclophosphamide (C) (AC), docetaxel (D), and alternating AC and D (AC-D) as frontline chemotherapy for metastatic breast cancer (MBC): Japan Clinical Oncology Group trial (JCOG9802). Proc ASCO 2005;Abstract 521.

Lim H et al. A phase II study of docetaxel (T) and capecitabine (X) combination chemotherapy as first-line chemotherapy for patients (pts) with metastatic breast cancer (MBC). Proc ASCO 2005;Abstract 889.

Miller KD et al. E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Presentation. Proc ASCO 2005. No abstract available

Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9. Abstract

Minea LN et al. Capecitabine monotherapy for elderly patients with metastatic breast cancer. Proc ASCO 2004;Abstract 797.

Moinpour C et al. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Quality of life (QoL) and pain palliation results from the global phase III study. Proc ASCO 2004;Abstract 621.

Moulder SL et al. Results of a planned efficacy and safety analysis for a National Comprehensive Cancer Network sponsored phase II study of gemcitabine and irinotecan (GI) in metastatic breast cancer (MBC). Proc ASCO 2005;Abstract 679.

Nabholtz JM et al; TAX 306 Study Group. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. J Clin Oncol 2003;21(6):968-75. Abstract

Nole F et al. Dose finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine in metastatic breast cancer (MBC) patients: Final results. Proc ASCO 2005;Abstract 666.

O’Shaughnessy JA et al. Weekly nanoparticle albumin paclitaxel (Abraxane) results in longterm disease control in patients with taxanerefractory metastatic breast cancer. San Antonio Breast Cancer Symposium 2004;Abstract 1070.

O’Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract

Paley M et al. Preferences for oral and parenteral antitumor therapy: A survey of 260 patients with metastatic breast cancer. Proc ASCO 2005;Abstract 619.

Palmeri S et al. Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: Results of a multicenter phase II study. Oncology 2005;68(4-6):438-45. Abstract

Perez EA et al. A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932. Oncology 2005;69(2):117-21. Abstract

Pierga JY et al; Cooperative Group of the French capecitabine compassionate use program. Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program. Breast Cancer Res Treat 2004;88(2):117-29. Abstract

Rossi A et al. Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer. Anticancer Res 2003;23(2C):1657- 64. Abstract

Segalla JGM et al. Effect of capecitabine (X) on quality of life (QoL) in patients (pts) with metastatic breast cancer (MBC). Proc ASCO 2004;Abstract 8130.

Seidman AD et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc ASCO 2004;Abstract 512.

Seidman AD et al. Single-agent capecitabine: A reference treatment for taxane-pretreated metastatic breast cancer? Oncologist 2002;7(Suppl 6):20-8. Abstract

Sikov WM et al. Gemcitabine and capecitabine in metastatic breast cancer (MBC): A Brown University Oncology Group (BrUOG) phase II study. Proc ASCO 2005;Abstract 785.

Sledge GW et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An Intergroup trial (E1193). J Clin Oncol 2003;21(4):588-92. Abstract

Stemmler J et al. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer. Oncology 2005;68(1):71- 8. Abstract

Talbot DC et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002;86(9):1367-72. Abstract

Tong DK et al. Phase II study of an ‘all-oral’ regimen of capecitabine, idarubicin and cyclophosphamide for metastatic breast cancer — Safety, efficacy and quality of life. Oncology 2005;68(4-6):520-5. Abstract

Vukelja S et al. Activity of oral irinotecan (IRI) in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and capecitabine: Phase 2 study results. Proc ASCO 2005;Abstract 562.

Winer EP et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and leukemia group B trial 9342. J Clin Oncol 2004;22(11):2061-8. Abstract

Zamora P et al. Capecitabine (X) as single agent in elderly patients (p) with metastatic breast cancer (MBC). Proc ASCO 2005;Abstract 843.

Zielinski C et al. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: A Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. J Clin Oncol 2005;23(7):1401-8. Abstract